Between June 20 and 22, 2018, European conference was held for ALS (ENCALS) at Oxford University in England. During the conference, the company presented its scientific work on ALS cell therapy. The work presented describes the comprehensive scientific research led by Prof. Michel Revel, Chief Scientist of the company, and Dr. Michal Izrael, VP of R&D in the field of neurodegenerative diseases in the company, on the company's flagship product, AstroRx®. The work presented at the conference by Dr. Guy Slutsky, was awarded a prize for excellence among the hundreds of research papers presented at the conference (http://www.www.encals.eu). The work describes the safety and efficacy results of the product in model animals and its various mechanisms of action, which prevent the death of motor neurons that are damaged in ALS. The results described in the article constitute the foundation of the clinical trial the company is currently conducting in ALS patients using AstroRx®. The clinical trial is being conducted in the Department of Neurology of the Hadassah Ein-Kerem Medical Center, and interim results are expected during the coming year.
Professor Michel Revel, the company's Chief Scientist, noted: "Winning the award for excellence in an international conference that deals with treatments for severe neurological disease (ALS) is testimony to the recognition of a breakthrough by Kadimastem and proves the scientific community's assessment of the company's product development."
Yossi Ben Yossef' the company's CEO, stated: "I am pleased and happy with the decision of the scientific committee of the conference and see this as an vote of confidence and recognition by the scientific community of the importance of the company's technology for the treatment of ALS.”